[en] [en] PURPOSE: Hereditary hemorrhagic telangiectasia (HHT) is under-recognized, and specialized referral centers are limited, specifically in Belgium. The primary aim of this study was to describe the clinical characteristics of our patients with HHT, in particular the prevalence of vascular malformations (VMs). Secondary objective was to describe associations between patient's current work-up and anemia.
METHODS: We performed a retrospective analysis of 118 patients treated at our center between 2015 and 2024. We analyzed documented VM and correlation with genetic work-up, prevalence of epistaxis, and referral of patients to specialist ENT services. We studied the correlation between anemia and clinical parameters such as documented digestive telangiectasia.
RESULTS: The main results confirmed the dominance of epistaxis among the documented symptoms. Anemia was correlated with age and presence of documented digestive telangiectasia. Only 55% of patients with epistaxis were referred to an otorhinolaryngologist. The majority of patients (65%) had documented multisystem involvement of at least 2 organs, and the majority of important VMs (lung and liver) were documented properly. However, liver malformations remain not documented in 41% of cases and lung malformations in 31% of cases. In our cohort, 61% of patients underwent genetic analysis (80% ENG and/or ACVRL1). However, there was no significant association between genetic and multisystem work-up or specific phenotype.
CONCLUSIONS: We highlighted the importance of epistaxis as a cardinal symptom in the management of HHT. We also highlighted strengths and gaps that could lead to future improvements, such as systematic referral of patients with epistaxis to ENT and improved coordination of care. Further longitudinal studies would allow us to assess the impact of improved pathways to improve patient care nationwide.
Disciplines :
Otolaryngology
Author, co-author :
Palm, Clément ; Medical school, University of Liège, Belgium
Rogister, Florence ; Université de Liège - ULiège > Département des sciences cliniques ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'ORL, d'audiophonologie et de chir. cervico-faciale
Language :
English
Title :
Reviewing the Efficiency of the Initial Work-Up for Hereditary Hemorrhagic Telangiectasia in a Tertiary Referral University Center in Belgium.
Al Tabosh T, Al Tarrass M, Tourvieilhe L, Guilhem A, Dupuis-Girod S, Bailly S. Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances. J Clin Invest. 2024; 134(4):e176379. doi:10.1172/JCI176379
Hermann R, Shovlin CL, Kasthuri RS, et al. Hereditary haemorrhagic telangiectasia. Nat Rev Dis Primers. 2025; 11(1):1-19. doi:10.1038/s41572-024-00585-z
Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective. Haematologica. 2018; 103(9):1433-1443. doi:10.3324/haematol.2018.193003
Gong AJ, Garg T, Khalil A, et al. Health-related quality of life outcome measures in individuals with hereditary hemorrhagic telangiectasia: a scoping review. Am J Rhinol Allergy. 2024; 38(1):60-76. doi:10.1177/19458924231207123
Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, Feige JJ. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2020; 15(1):4. doi:10.1186/s13023-019-1281-4
Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000; 91(1):66-67. doi:10.1002/(sici)1096-8628(20000306)91:1<66::aid-ajmg12>3.0.co;2-p
Faughnan ME, Mager JJ, Hetts SW, et al. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020; 173(12):989-1001. doi:10.7326/M20-1443
Dupuis-Girod S, Cottin V, Shovlin CL. The lung in hereditary hemorrhagic telangiectasia. Respiration. 2017; 94(4):315-330. doi:10.1159/000479632
Kofoed MS, Tørring PM, Christensen AA, Lange B, Kjeldsen AD, Nielsen TH. High risk of ischaemic stroke amongst patients with hereditary haemorrhagic telangiectasia. Eur J Neurol. 2024; 31(2):e16128. doi:10.1111/ene.16128
Erasme D. List of competence centers. 2024. Accessed October 1, 2024. https://amro-hht-france.org/ou-se-faire-soigner-les-nouveaux-centres-de-competences/
Schultze Kool L. Hereditary hemorrhagic telangiectasia working group. 2024. Accessed October 1, 2024. https://vascern.eu
Merlo CA, Yin LX, Hoag JB, Mitchell SE, Reh DD. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol. 2014; 4(11):921-925. doi:10.1002/alr.21374
Tunkel DE, Anne S, Payne SC, et al. Clinical practice guideline: nosebleed (epistaxis) executive summary. Otolaryngol Head Neck Surg. 2020; 162(1):8-25. doi:10.1177/0194599819889955
Chitsuthipakorn W, Hoang MP, Kanjanawasee D, Seresirikachorn K, Snidvongs K. Treatments of epistaxis in hereditary hemorrhagic telangiectasia: systematic review and network meta-analysis. Curr Allergy Asthma Rep. 2023; 23(12):689-701. doi:10.1007/s11882-023-01116-8
Dür C, Anschuetz L, Negoias S, Bulut OC, Angelillo-Scherrer A, Caversaccio M. Long-term efficacy assessment of current treatment options for epistaxis in HHT. Eur Arch Otorhinolaryngol. 2021; 278(11):4321-4328. doi:10.1007/s00405-021-06701-z
Hayama M, Maeda Y, Obata S, et al. Understanding hereditary hemorrhagic telangiectasia: from genetic anomalies to systemic manifestations, quality of life, and epistaxis management—exploring the otolaryngologist’s integral role. Auris Nasus Larynx. 2024; 51(2):305-312. doi:10.1016/j.anl.2023.11.002
McDonald J, Kornish J, Stevenson DA, et al. Frequency of epistaxis and telangiectasia in patients with hereditary hemorrhagic telangiectasia (HHT) in comparison with the general population: Curaçao diagnostic criteria revisited. Genet Med. 2023; 25(8):100865. doi:10.1016/j.gim.2023.100865
Latif MA, Sobreira NLD, Guthrie KS, et al. Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: experience from an HHT Center of Excellence. Am J Med Genet A. 2021; 185(7):1981-1990. doi:10.1002/ajmg.a.62193
McDonald J, Stevenson DA. Hereditary Hemorrhagic Telangiectasia. 2000 Jun 26 [updated 2021 Nov 24]. In: Adam MP, Feldman J, Mirzaa GM, et al, eds. GeneReviews® [Internet]. University of Washington, Seattle; 1993–2025.
Mora-Luján JM, Iriarte A, Alba E, et al. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia: risk factors and endoscopic findings. J Clin Med. 2019; 9(1):82. doi:10.3390/jcm9010082
Hermann R, Shovlin CL, Kasthuri RS, et al. Hereditary haemorrhagic telangiectasia. Nat Rev Dis Primers. 2025; 11(1):1. doi:10.1038/s41572-024-00585-z